PTC Therapeutics announces preliminary 2024 revenue of $814M, exceeding guidance, and 2025 financial outlook

PTC THERAPEUTICS, INC.

2024-FY EPS reported -$4.73 revenue$806,780,000

Preliminary 2024 total revenue ~$814M, net product revenue ~$601M, and Evrysdi royalties ~$211M.
Four FDA approval applications submitted in 2024, including sepiapterin for PKU with FDA action date July 29, 2025 and CHMP opinion expected Q2 2025.
License and collaboration agreement with Novartis for PTC518 (Huntington's disease) closed, with $1B upfront and up to $1.9B milestones.
2025 revenue guidance $600M-$800M; GAAP R&D and SG&A expense $805M-$835M; non-GAAP $730M-$760M.
PIVOT-HD Phase 2 data readout expected Q2 2025; cash balance ~$1.1B plus additional $1B from Novartis upfront.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.